Clinical trials: Galectin 3
Idiopathic Pulmonary Fibrosis (IPF)
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
This is a randomized, double-blind, placebo-controlled phase 2b trial in subjects with IPF (idiopathic pulmonary fibrosis) investigating the efficacy and safety of GB0139.
- Trial name
- NCT03832946
- Testing
- GB0139
- Where
- 128 sites in United States, Australia and 13 more
- Volunteers
- 172 people
- Sponsor
- Galecto Biotech AB
Stable Angina
Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases
Through the literature review , we pick out a series of forward-looking biological indicators as follows : 1. NGAL 2. Cystatin C: 3. Galectin-3: 4. Copeptin: 5. MR-Pro ANP: 6. sST2:
- Trial name
- NCT02179047
- Testing
- coronary angiography
- Where
- Taiwan
- Volunteers
- 214 people
- Sponsor
- Taipei City Hospital
Idiopathic Pulmonary Fibrosis
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
This study will be divided into 2 parts. Part 1 is a randomized, double-blind, single centre, placebo-controlled, single ascending dose (SAD) phase I study designed to assess the safety, tolerability, PK and PD (Pharmacodynamic)…
- Trial name
- NCT02257177
- Testing
- Inhaled TD139
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Galecto Biotech AB